68259-66-5

Basic information

• Product Name: N-benzyl-2-oxopropanamide
• Synonyms: N-benzyl-2-oxopropanamide
• CAS NO: 68259-66-5
• Molecular Weight: 177.203
• Mol File: 68259-66-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: N-benzyl-2-oxopropanamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-benzyl-2-oxopropanamide(68259-66-5)
• EPA Substance Registry System: N-benzyl-2-oxopropanamide(68259-66-5)

Safety Data

• Hazardous Substances Data: 68259-66-5(Hazardous Substances Data)

Upstream product

• 100-46-9 benzylamine 
• 123-54-6 acetylacetone 
• 103808-45-3 (S)-N-benzyl-2-hydroxypropionamide 
• 87605-11-6 propynoic acid benzylamide 
• 127-17-3 2-oxo-propionic acid 

Relevant articles and documents

Synthesis of 1,2,5-thiadiazole-3(2H)-thiones and 1,2,5-thiadiazol-3(2H)-ones from 1,2,3-dithiazoles

5H-1,2,3-Dithiazole-5-thiones and 5H-1,2,3-dithiazol-5-ones undergo a new transformation into 1,2,5-thiadiazole-3(2H)-thiones and 1,2,5-thiadiazol-3(2H)-ones, respectively, upon treatment with primary amines; the structure of thiadiazolethione was confirm

Selective amidation by a photocatalyzed umpolung reaction

A metal-catalyzed organic transformation merged with another organophotocatalyst has been developed under mild conditions for production of α-ketoamides. CuI-catalyzed highly selective and rapid COCH2-amidation in the presence of electrophilic CαO bonds, which is synchronized by an eosin Y (EY)-photocatalyst, furnishes a wide range of labile α-ketoamides, unsymmetrical oxalamides and chiral analogues on the treatment of 1,3-dicarbonyls with amines, PhIO and LED light at room temperature. The current strategy opens up a new avenue to making photocatalysis a common synthetic tool for large-scale production in academia and industry.

HETEROCYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of Formula (I) or stereoisomers or prodrugs or solvates or pharmaceutically acceptable salts thereof, wherein A, B, J, K, Z, R, Ra, Rb, Rc, and Rd, are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.